The announcement “Appendix 3Y — Change of Director’s Interest Notice” has been lodged with the Australian Securities Exchange.
Read Appendix 3Y — Change of Director’s Interest Notice.
Appendix 3Y — Change of Director's Interest Notice
Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.